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Objective: We studied the beneﬁt of bacillus CalmetteeGuerin (BCG) maintenance therapy to determine
the ideal maintenance therapy schedule.
Methods: We retrospectively reviewed non-muscle-invasive bladder cancer patients who underwent
transurethral resection of bladder tumors and BCG instillation treatment at Chang-Gung Memorial
Hospital, Linkou, Taiwan, from January 1997 to December 2009. All patients in the study had non-
muscle-invasive urothelial carcinoma of the bladder or carcinoma in situ. We compared the recurrence-
free rate of patients who received induction alone and with maintenance BCG therapy sessions. In
addition, we analyzed the best number of maintenance therapy sessions that gave the lowest cancer
recurrence.
Results: This study included 427 patients with a mean age of 64 years. The median number of BCG
treatments was 11, and the ratio of male to female was 3:1. Receiving an induction dose alone was a
signiﬁcant factor for tumor recurrence with a hazard ratio of 3.77. The recurrent risk rate of patient who
received BCG therapy 13e15 times had lower recurrence rate than other groups.
Conclusion: A maintenance dose gave patients a signiﬁcant beneﬁt over those who just received in-
duction therapy. BCG maintenance therapy worked best if given 13e15 times in our study.
Copyright © 2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Approximately 75e85% of patients with bladder cancer present
with the disease conﬁned to the mucosa1 or submucosa (stage T1).2
Transurethral resection (TUR) of bladder tumors, with or without
intravesical adjuvant therapy, is still the primary treatment for
non-muscle-invasive bladder tumor. According to many published
results of randomized trials, it has become clear that intravesical
bacillus CalmetteeGuerin (BCG) is a better therapeutic choice for
high risk Ta, T1 papillary carcinomas as well as for carcinoma in situ
(CIS)3 compared with TUR alone4,5 or chemotherapy.6,7 For optimal
efﬁcacy, an induction course followed by maintenance BCG is rec-
ommended. Lamm et al8 reported in the Southwest Oncologyang Gung Memorial Hospital,
jacobpang@adm.cgmh.org.tw
ciation. Published by Elsevier TaiwGroup study that 3-year BCG maintenance therapy markedly pro-
longed the recurrence-free survival and time to disease progression
in comparison with conventional induction therapy. The mainte-
nance therapy signiﬁcantly prolonged the post-TUR recurrence-
free survival compared with BCG induction therapy alone.9
However, patients may not complete the entire BCG mainte-
nance regimen due to several reasons. Some adverse events may
occur after treatment and present as the most frequent conditions
for therapy withdrawal. The longer the instillations are given, the
more likely a severe toxicity will develop in the patients.8 Some
studies reported decreased recurrence and progression with
maintenance therapy. Herr et al10 reported that BCG treatment
without maintenance in patients with high-risk nonemuscle-
invasive bladder cancer compared favorably with trials in which
comparable patients received maintenance BCG.
Most practice guidelines recommend maintenance BCG for 1e3
years.2,8,11 However, only few studies commented on the duration
of dose of maintenance BCG used. Among them, the largest study
was reported by Lamm et al that 3-year BCG maintenance therapyan LLC. Open access under CC BY-NC-ND license.
Table 1
Clinicodemographic characteristics.
Baseline characteristics Statistics
Age at BCG treatment (y) 64.4 ± 12.0
Sex
Male 312 (73.1)
Female 115 (26.9)
BCG treatments
6 (induction) 137 (32.1)
>6 (maintenance) 290 (67.9)
Multiplicity
1 230 (55.0)
2 188 (45.0)
Category
Urothelial carcinoma 391 (92.7)
Concomitant carcinoma in situ 31 (7.3)
Grade
Low 179 (43.9)
High 229 (56.1)
Stage
Ta 136 (46.7)
T1 155 (53.3)
Bladder cancer history 280 (65.6)
Had received intravesical therapy 62 (14.5)
Mean follow-up (mo) 43.10
Median follow-up (mo) 31.7 (0.23e160.46)
Treatment times 10.8 ± 4.5
Data are presented as n (%) or mean ± SD.
BCG ¼ bacillus CalmetteeGuerin.
Table 2
Comparison of bacillus Calmette-Guerin (BCG) induction therapy and maintenance
therapy.
BCG induction
(n ¼ 137)
BCG maintenance
(n ¼ 290)
p
Age at BCG instillation (y)a,* 67.15 ± 11.47 63.17 ± 12.03 0.001
Sexb 0.981
Male 100 (73.0) 212 (73.1)
Female 37 (27.0) 78 (26.9)
History of bladder tumorb 88 (64.2) 192 (66.2) 0.689
Smokingb 49 (36.6) 100 (35.3) 0.806
Exposure to dying agentsb 8 (7.1) 17 (7.4) 0.917
Multiplicityb 0.421
1 piece 71 (52.2) 159 (56.4)
2 pieces 65 (47.8) 123 (43.6)
Unknown cases 1 8
Size (the biggest diameter, cm)a 2.17 ± 1.58 1.93 ± 1.16 0.139
Categoryb 0.232
UC 129 (94.9) 262 (91.6)
UC concomitant CIS 7 (5.1) 24 (8.4)
Unknown cases 1 4
Gradeb 0.288
Low 62 (47.7) 117 (42.1)
High 68 (52.3) 161 (57.9)
Unknown cases 10 12
Stageb 0.823
Ta 42 (47.7) 94 (46.3)
T1 46 (52.3) 109 (53.7)
Unknown cases 49 87
Previous intravesical
chemotherapyb
27 (19.7) 35 (12.1) 0.036
Median follow-up (mo)* 20.240 37.850 <0.001
Data are presented as n (%) or mean ± SD.
*p < 0.05, signiﬁcant.
CIS ¼ carcinoma in situ; UC ¼ urothelial carcinoma.
a Two-sample independent t test, mean ± standard deviation.
b Chi-square test, n (%).
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was to prove that BCG maintenance therapy is more beneﬁcial
than induction only and to investigate the optimal duration for
maintenance therapy.
2. Patients and methods
A retrospective cohort study was performed, with 427 consec-
utive patients with bladder cancer were evaluated from 1997 to
2009. They underwent TUR and were found to have non-muscle-
invasive bladder cancer (Ta, T1, and/or Tis). Subsequently, they
received six weekly instillations of Connaught strain (81 mg) BCG
therapy as induction therapy and were evaluated for response after
3 months by cystoscopy, urine cytology, and TUR biopsy. Patients
then received three weekly maintenance therapies every 3e6
months and up to 21 times if possible. The total therapy course was
nearly 2 years. Patients were also followed every 3e6 months with
cystoscopy, repeated TUR as needed, and urine cytology if possible.
After ﬁnishing the BCG intravesical instillation therapy, there was
no other intravesical chemotherapy during follow-up duration.
Patients with previous bladder cancer histories will receive the
intravesical chemotherapy, such as mitomycin C or epirubincin. We
excluded patients who had previously received BCG intravesical
instillation therapy. Each patient's data were entered into a data-
base, and clinical information was recorded from charts. Patients
upstaged to muscle invasion (T2) at the beginning of TUR, under-
going immediate cystectomy without receiving BCG, receiving
incomplete induction BCG therapy, or missing follow-up within 1
month were all excluded from this analysis.
The end point was deﬁned as local recurrence or progression.
Tumor recurrence was deﬁned as any tumor on biopsy or positive
urine cytology during follow-up examinations. Progression was
deﬁned as a muscle-invasive tumor or metastasis. Pathological
staging was based on the TNM classiﬁcation and tumor grade was
determined in accordance with the WHO classiﬁcation. Patients
who died from other causes were deﬁned as censored data. Follow-
up durationwas calculated by the subtraction of local recurrence or
progression date (expired date, the last clinics follow-up date) and
the last date of BCG therapy.
Statistical analysis was performed using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA). Baseline characteristics were represented as
mean ± standard deviation for continuous data and n (%) for cat-
egorical data (Table 1). Originally, we divided patients into two
groups, the induction group (with 6 BCG treatments) and the
maintained group (>6 BCG treatment). Chi-square test was used to
compare categorical variables, and two-sample independent t test
for continuous variable. Recurrence-free plot was based on the
KaplaneMeier method with the log rank test. Furthermore, we
divided patients into several groups according to the numbers of
BCG treatment. The ﬁrst group completed six BCG treatments,
followed by maintenance groups from one to three treatments,
from four to six treatments, from seven to nine treatments, and10
treatments. Cox proportional hazard model was used to estimate
the hazard ratios of recurrence. A p value <0.05 was considered
signiﬁcant.
3. Results
From January 1997 to December 2009, 427 patients were eval-
uated. Among them, 312 were males and 115 females. There were
106 patients with recurrent and 321 patients without recurrent
tumor. Mean age was 64.4 years and mean follow-up time was 31.7
months. Median number of treatments was 11. There were 280
(65.6%) patients with history of bladder tumor. Most patients had
urothelial carcinoma and only 31 patients (7.3%) were concomitantwith CIS. Of the 427 patients, 290 enteredmaintenance therapy and
137 patients received induction therapy only. Main characteristics
of the patients are given in Table 1.
Table 2 shows the characteristics of the patients with induction
therapy only and those who entered maintenance therapy. More
patients in the maintenance group had high grade, advanced stage,
Table 3
Cumulative recurrence-free rate of bacillus CalmetteeGuerin (BCG) treatment
times.a
Cumulative recurrence-
free rate
n Follow-up after BCG treatment (%)
1 y 5 y 10 y
Overall 427 81.7 72.9 70.0
6 BCG treatment times
(induction)
137 64.6 52.1 48.9
>6 BCG treatment times
(maintenance)
290 89.6 82.6 80.0
a Log-rank test for recurrence-free rate between the induction and maintenance
therapies is p < 0.001.
Fig. 1. Recurrence-free rate between bacillus CalmetteeGuerin (BCG) induction and
maintenance therapy. Patients on maintenance BCG therapy had higher recurrence-
free rate than those who just received induction therapy.
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group had better recurrence-free rates than the induction group.
The recurrent free rates were 64.6% versus 89.6%, 52.1% versus
82.6%, 48.9 versus 80.0% in 1 year, 3 years, and 10 years respectively
(Table 3).Table 4
Clinicodemographic characteristics of each group.
BCG induction BCG maintenance:
1e3 (n ¼ 76)
Age at BCG instillation (y) 67 ± 11 65 ± 13
Sex
Male 100 (73.0) 56 (73.7)
Female 37 (27.0) 20 (26.3)
History of bladder tumor 88 (64.2) 52 (68.4)
Smoking 49 (36.6) 22 (29.7)
Multiplicity
1 piece 71 (52.2) 44 (58.7)
2 pieces 65 (47.8) 31 (41.3)
Size (cm) 2 ± 2 2 ± 1
Category
UC concomitant CIS 3 (02.2) 3 (03.9)
UC 129 (94.9) 69 (90.8)
Grade
Low 62 (47.7) 29 (40.3)
High 68 (52.3) 43 (59.7)
Stage
Ta 42 (47.7) 30 (54.5)
T1 46 (52.3) 25 (45.5)
Previous intravesical chemotherapy 27 (19.7) 15 (19.7)
Data are presented as n (%) or mean ± SD.
BCG ¼ bacillus CalmetteeGuerin; CIS ¼ carcinoma in situ; UC ¼ urothelial carcinoma.Fig. 1 shows the signiﬁcantly lower recurrent free rate in pa-
tients who received induction therapy only by KaplaneMeier test.
The characteristic of each group is shown in Table 4. Table 5
reveals the signiﬁcantly lower recurrence rates for each of the
further classiﬁed subgroups of maintenance therapy compared
with the patients of the induction group, whereas the group with
BCG maintenance therapy from seven to nine times had the lowest
hazard ratio (Fig. 2). The recurrence-risk for patients who received
BCG maintenance therapy from seven to nine times was 84% lower
compared with the patients who only received induction BCG
therapy. The other groups were lower by 67%, 71%, and 83% after
BCG maintenance therapy from one to three times, from four to six
times, and 10 times respectively. The group with BCG mainte-
nance therapy from seven to nine times had the lowest recurrence-
risk rate.
4. Discussion
Herr et al12 reported that maintenance BCG does not appear
superior to initial BCG treatments in preventing or delaying tumor
progression. Herr et al10 also revealed that BCG treatment without
maintenance for patients with high-risk nonemuscle-invasive
bladder cancer compared favorably with trials inwhich comparable
patients received maintenance BCG.10
Nevertheless, many studies have found BCG therapy to be
effective in reducing the risk of disease progression only when
maintenance schedules were applied.3 Hinotsu et al9 demonstrated
that BCG intravesical instillation maintenance therapy was able to
prolong post-TUR recurrence-free survival signiﬁcantly in patients
with recurrent or multiple, stage Ta or T1, bladder cancer. Also, a
number of reports have shown that BCG must be given in a main-
tenance schedule for optimal efﬁcacy.2
Our study revealed that patients who received maintenance
BCG therapy had signiﬁcantly higher recurrence-free rate. Two-
year recurrence-free rates of approximately 80% and 60% were
estimated for the maintenance group and the nonmaintenance
group, respectively in the study by Lamm et al.8 In addition, Saint
et al13 carried out a clinical study that administered the BCG Con-
naught strain according to a 3-yearmaintenance schedule, and they
reported a 2-year recurrence-free rate of 84.9%. Furthermore, van
der Meijden et al14 reported an estimated 2-year recurrence-freeBCG maintenance:
4e6 (n ¼ 79)
BCG maintenance:
7e9 (n ¼ 84)
BCG maintenance:
 10 (n ¼ 51)
64 ± 12 62 ± 12 61 ± 12
58 (73.4) 63 (75.0) 35 (68.6)
21 (26.6) 21 (25.0) 16 (31.4)
45 (57.0) 63 (75.0) 32 (62.7)
27 (35.1) 29 (34.9) 22 (44.9)
45 (59.2) 42 (50.6) 28 (58.3)
31 (40.8) 41 (49.4) 20 (41.7)
2 ± 1 2 ± 1 2 ± 1
2 (02.5) 3 (03.7) 2 (04.0)
71 (89.9) 76 (93.8) 46 (92.0)
30 (39.0) 33 (41.3) 25 (51.0)
47 (61.0) 47 (58.8) 24 (49.0)
22 (38.6) 30 (50.8) 12 (37.5)
35 (61.4) 29 (49.2) 20 (62.5)
14 (17.7) 5 (06.0) 1 (02.0)
Table 5
Estimated hazard ratio (HR) for numbers of maintenance bacillus CalmetteeGuerin
therapy sessions.
BCG treatment group Model I Model IIa
Estimated HR
(95% CI)
p Estimated HR
(95% CI)
p
Group 1 1 1
Group 2 vs. Group 1 0.33 (0.19e0.58) >0.001 0.26 (0.13e0.54) >0.001
Group 3 vs. Group 1 0.29 (0.16e0.52) >0.001 0.28 (0.14e0.56) >0.001
Group 4 vs. Group 1 0.16 (0.08e0.33) >0.001 0.12 (0.05e0.32) >0.001
Group 5 vs. Group 1 0.17 (0.07e0.39) >0.001 0.10 (0.02e0.41) 0.001
Sex 1.47 (0.86e2.52) 0.156
Age 1.00 (0.98e1.02) 0.932
Grade 1.45 (0.83e2.52) 0.193
Stage 1.14 (0.68e1.93) 0.616
Mutiplicity (2 vs. 1) d 2.27 (1.36e3.79) 0.002
Chemotherapy d 1.94 (1.09e3.45) 0.025
CI ¼ conﬁdence interval; Group 1 ¼ BCG induction; Group 2 ¼ BCG maintenance
from one to three times; Group 3 ¼ BCG maintenance from four to six times; Group
4 ¼ BCG maintenance from seven to nine times; Group 5 ¼ BCG maintenance 10
times.
a Model II adjusted by sex, age, grade, stage, multiplicity, and chemotherapy.
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strain. Hinotsu et al9 also reported a 2-year recurrent free rate of
92.7%. In our study, the 2-year recurrent free rates were 88.3% and
63.5% for the maintenance group and the nonmaintenance group,
respectively, demonstrating ﬁndings similar to the results of the
previous studies.
Although maintenance dose can reduce the recurrence rate, no
large-scaled studies have shown the optimal times of standard
maintenance dose. European Association of Urology guidelines still
suggest that BCG should be given on a maintenance schedule in
recent reports.15e18 In addition, Bohle and Bock18 reported that
administration of BCG maintenance therapy for at least 1 year
resulted in signiﬁcantly superior suppression on the risk of disease
progression. Moreover, Sylvester et al17 reported that the BCG
group showed statistically signiﬁcant suppression of disease pro-
gression and, for patients who received some form of BCG main-
tenance therapy for at least 1 year, striking efﬁcacy was
demonstrated. In our study, patients who received BCG mainte-
nance therapy from seven to nine times had the lowest recurrence
rate in patients with non-muscle-invasive bladder tumor. However,
this trend was not seen after adjusting by sex, age, tumor grade,
tumor stage, and tumor number.Fig. 2. Recurrence-free rate between different maintenance therapy courses. The
group given bacillus CalmetteeGuerin (BCG) maintenance from seven to nine times
had a higher recurrence-free rate than the other groups.The major limitation of our study was the small amount of pa-
tients included, although nearly 500, as compared with other
studies. Patient classiﬁcation bias was also another limitation in our
study due to retrospective study. It needed to have large number
patients and a prospective study to conﬁrm our result.
In conclusion, this study demonstrated that BCG intravesical
instillation maintenance therapy may signiﬁcantly increase post-
TUR recurrence free rate in patients with bladder cancer. The
duration of maintenance BCG therapy is important in preventing
the recurrent of nonemuscle-invasive bladder cancer. However, the
optimal duration of maintenance therapy needs further reﬁnement
and validation.
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